Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 43Prostatic Neoplasms 41Carcinoma, Non-Small-Cell Lung 36Breast Neoplasms 34Lymphoma 28Leukemia, Myeloid, Acute 25Lymphoma, Non-Hodgkin 21Melanoma 18Colorectal Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Ovarian Neoplasms 15Lung Neoplasms 15Hodgkin Disease 15Hematologic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Neoplasms 13Neoplasm Metastasis 13Myelodysplastic Syndromes 13Sarcoma 12Leukemia, Lymphocytic, Chronic, B-Cell 12Wilms Tumor 11Head and Neck Neoplasms 11Carcinoma, Renal Cell 11Burkitt Lymphoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Leukemia 9Glioma 9Fallopian Tube Neoplasms 9

Interventions

Gemtuzumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Acute × 30 days × Clear all
NCT00658814 2026-05-29

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
133 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡